Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3241-3250 Newer>

Pharmaceutical Executive November 1, 2006	Thoughtleader: Making Things Stick Ambrx has created the "glue" that allows researchers to attach activity-enhancing molecules to amino acids where they couldn't before.
Pharmaceutical Executive November 1, 2006 Peter J. Pitts	Opinion: AARPeeved A look at the shortcomings of the AARP's regular "Trends" reports on prescription-drug pricing.
Pharmaceutical Executive November 1, 2006 Cook & Witten	Legal: Keyword: "Infringement?" Google and other search engines sell pharma companies' trademarks as keyword search terms. Seems okay. If not for one thing: Guess who's buying? Your direct competitors.
Pharmaceutical Executive November 1, 2006 Marcee Nelson	Direct to Consumer: Emotional Connection By reaching out to women, pharma companies can build more meaningful brands.
Pharmaceutical Executive November 1, 2006 Mike Mallett	Marketing to Professionals: Penetrate the Point of Purchase Leverage mystery shoppers, and improve patient compliance through local pharmacists.
Pharmaceutical Executive November 1, 2006	Alternative Media: Time to Change the Channel Upgraded hospital television and Internet systems equal new marketing opportunities.
Pharmaceutical Executive November 1, 2006 Barricklow & Bandy	Meetings: Before and After Maximize sales meetings by focusing on strong pre- and post-meeting initiatives.
Pharmaceutical Executive November 1, 2006 Joanna Breitstein	Back Page: The Case for Diversity Variety is the spice of life - and the future of Big Pharma.
The Motley Fool November 1, 2006 Brian Lawler	Le Generic Excuse for Sanofi Even with its massive pipeline, there may be problems ahead for Sanofi. Its two top drugs are exposed to generic threats as Sanofi fights in court to keep generic competitiors out of those markets. Investors, take note.
The Motley Fool November 1, 2006 Brian Lawler	Waiting for CVT's Trial Results The biopharm reported third-quarter 2006 earnings that were mostly as expected. Investors are just awaiting the clinical trial results from the company's large phase 3 Merlin study testing its marketed angina drug, Ranexa.
<Older 3241-3250 Newer> Return to current articles.